Under the auspices of the Saudi Society of Rheumatology, Saudi Society of Dermatology and Dermatologic Surgery, Saudi ...

Fintel reports that on November 4, 2024, Argus Research upgraded their outlook for AbbVie (NYSE:ABBV) from Hold to Buy.

We recently compiled a list of the 10 Best Pharma Stocks To Buy Right Now. In this article, we are going to take a look at ...

The University of Chicago Medicine’s incoming cancer center is getting a new name thanks to a $75 million donation from the ...

AstraZeneca is under scrutiny in China — as its top executive there and other personnel are being investigated by authorities ...

On Friday, AbbVie Inc (ABBV) stock saw a decline, ending the day at $203.55 which represents a decrease of $-0.32 or -0.16% from the prior close of $203.87. The stock opened at $204.37 and touched a ...

EvolveImmune Therapeutics Inc., a Branford-based bioscience company developing therapeutics to overcome cancer cell resistance to current immunotherapies, has signed a collaboration and ...

Discover the major biotech partnerships, collaborations, and mergers and acquisitions that made headlines in October 2024.

Their discoveries have already led to the departure of a Stanford president, sparked charges from the Department of Justice, ...

Argus upgraded AbbVie (ABBV) to Buy from Hold with a $220 price target Two of the company’s key immunology products, Skyrizi and Rinvoq, have succeeded Humira as growth engines, with the former having ...

(Reuters) -Cigna projected 2025 profit growth of at least 10% on Thursday, after posting quarterly results that beat Wall ...

GSK acquired an experimental therapy from Chimagen Biosciences, paying $300 million upfront for the “T-cell engager” therapy, ...